Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT03135171 2021-09-10

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Phase 1 Completed

11 enrolled

Breast

Breast Neoplasms

NCT02167854 2021-07-09

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Phase 1 Completed

23 enrolled

Breast

Breast Neoplasms

NCT04905667 2021-05-27

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

Phase 1 Completed

87 enrolled

Breast

Breast Neoplasms

NCT00788931 2020-12-19

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

Phase 1 Completed

15 enrolled

Breast

Breast Neoplasms

NCT01602406 2020-12-19

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

Phase 1 Completed

64 enrolled

Gastrointestinal

Stomach Neoplasms

NCT02152943 2020-12-19

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Phase 1 Completed

37 enrolled

Breast

Breast Neoplasms

NCT01285466 2020-12-09

A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab

Phase 1 Completed

110 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00367471 2020-09-09

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

Phase 1 Completed

31 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00085020 2020-08-03

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

Phase 1 Completed

13 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00543504 2020-06-30

Bevacizumab in Multiple Phase I Combinations

Phase 1 Completed

343 enrolled

Advanced Cancer

NCT02025192 2020-06-04

A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

Phase 1 Completed

60 enrolled

Breast

Breast Neoplasms

NCT02605915 2020-02-05

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Phase 1 Completed

98 enrolled

Breast

Breast Neoplasms

NCT04175171 2019-12-18

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

Phase 1 Completed

32 enrolled

Breast

Breast Neoplasms

NCT01351350 2019-08-08

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Phase 1 Completed

68 enrolled 29 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT01434303 2019-05-20

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Phase 1 Completed

37 enrolled

Breast

Breast Neoplasms

NCT03013881 2019-04-03

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers

Phase 1 Completed

18 enrolled

Breast

Breast Neoplasms

NCT01971515 2018-09-19

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

Phase 1 Completed

101 enrolled

Breast

Breast Neoplasms

NCT02060253 2018-06-14

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Phase 1 Completed

9 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02738970 2018-06-12

A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

Phase 1 Completed

88 enrolled

Breast

Breast Neoplasms

NCT03014076 2017-01-09

Immunotherapy Vaccine and Herceptin in Breast Cancer

Phase 1 Completed

30 enrolled

Breast

Breastcancer

NCT00800436 2016-12-16

A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females

Phase 1 Completed

66 enrolled 14 charts

Breast

Breast Neoplasms

NCT00960960 2016-12-15

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

Phase 1 Completed

71 enrolled

Breast

Breast Neoplasms

NCT00928330 2016-11-02

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

Phase 1 Completed

57 enrolled

Breast

Breast Neoplasms

NCT01384253 2016-09-30

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Phase 1 Completed

18 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms

NCT01454804 2016-04-13

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Phase 1 Completed

43 enrolled

Advanced Cancers

NCT00426556 2015-12-28

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Phase 1 Completed

88 enrolled 10 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Phase 1 Completed

100 enrolled

HER-2 Gene Amplification

NCT00927589 2015-12-10

A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

Phase 1 Completed

59 enrolled 19 charts

Solid Cancers

Clinical Trials

Panther

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

IPATHER

Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)

B-PRECISE-01

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

A Safety Study of SGN-LIV1A in Breast Cancer Patients

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

THELMA

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

Bevacizumab in Multiple Phase I Combinations

A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

Immunotherapy Vaccine and Herceptin in Breast Cancer

A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer